Naomi Deirdre Fisher, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renin | 35 | 2022 | 637 | 3.330 |
Why?
|
| Hypertension | 42 | 2024 | 8359 | 2.550 |
Why?
|
| Renin-Angiotensin System | 25 | 2017 | 741 | 2.020 |
Why?
|
| Angiotensin II | 27 | 2017 | 867 | 1.720 |
Why?
|
| Renal Circulation | 26 | 2017 | 330 | 1.690 |
Why?
|
| Cacao | 7 | 2013 | 98 | 1.560 |
Why?
|
| Blood Pressure | 32 | 2023 | 8405 | 1.230 |
Why?
|
| Flavonoids | 5 | 2012 | 441 | 1.140 |
Why?
|
| Fumarates | 6 | 2016 | 138 | 1.030 |
Why?
|
| Captopril | 17 | 2017 | 266 | 1.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 8 | 2023 | 246 | 0.960 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 21 | 2016 | 1508 | 0.930 |
Why?
|
| Amides | 6 | 2016 | 455 | 0.890 |
Why?
|
| Sympathectomy | 5 | 2023 | 88 | 0.830 |
Why?
|
| Kidney | 25 | 2023 | 6984 | 0.820 |
Why?
|
| Antihypertensive Agents | 20 | 2023 | 2043 | 0.800 |
Why?
|
| Aldosterone | 19 | 2022 | 861 | 0.710 |
Why?
|
| Denervation | 5 | 2023 | 279 | 0.620 |
Why?
|
| Vasodilation | 10 | 2016 | 956 | 0.620 |
Why?
|
| Internet | 8 | 2001 | 3038 | 0.600 |
Why?
|
| Angiotensinogen | 8 | 2009 | 157 | 0.600 |
Why?
|
| Renal Plasma Flow | 5 | 2008 | 27 | 0.540 |
Why?
|
| Cerebrovascular Circulation | 3 | 2013 | 2713 | 0.520 |
Why?
|
| Hypertension, Renal | 3 | 2005 | 171 | 0.520 |
Why?
|
| Beverages | 3 | 2013 | 801 | 0.500 |
Why?
|
| Tetrazoles | 10 | 2011 | 861 | 0.450 |
Why?
|
| Telemedicine | 2 | 2023 | 2892 | 0.450 |
Why?
|
| Renal Artery | 5 | 2023 | 368 | 0.450 |
Why?
|
| Endothelium, Vascular | 5 | 2016 | 4414 | 0.440 |
Why?
|
| Dipeptides | 4 | 2005 | 405 | 0.440 |
Why?
|
| Program Development | 1 | 2019 | 1286 | 0.420 |
Why?
|
| Sodium, Dietary | 6 | 2010 | 420 | 0.410 |
Why?
|
| Angiotensin I | 4 | 2008 | 55 | 0.390 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2011 | 442 | 0.360 |
Why?
|
| Benzimidazoles | 7 | 2007 | 857 | 0.350 |
Why?
|
| Uric Acid | 3 | 2017 | 738 | 0.350 |
Why?
|
| Adrenal Glands | 4 | 2002 | 556 | 0.350 |
Why?
|
| Diet, Sodium-Restricted | 9 | 2007 | 289 | 0.340 |
Why?
|
| Vitamin D | 5 | 2017 | 3239 | 0.330 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2010 | 277 | 0.320 |
Why?
|
| Hyperuricemia | 2 | 2017 | 205 | 0.310 |
Why?
|
| Disease Management | 1 | 2019 | 2451 | 0.310 |
Why?
|
| Reference Values | 15 | 2010 | 4875 | 0.300 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2013 | 953 | 0.290 |
Why?
|
| Probenecid | 2 | 2017 | 73 | 0.290 |
Why?
|
| Biphenyl Compounds | 10 | 2011 | 943 | 0.280 |
Why?
|
| Cushing Syndrome | 1 | 2008 | 242 | 0.280 |
Why?
|
| Alcohol Drinking | 2 | 2017 | 3960 | 0.280 |
Why?
|
| Vasoconstrictor Agents | 6 | 2008 | 642 | 0.280 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 5236 | 0.260 |
Why?
|
| Hypercalcemia | 1 | 2008 | 415 | 0.260 |
Why?
|
| Allopurinol | 2 | 2017 | 186 | 0.260 |
Why?
|
| Catechin | 1 | 2005 | 66 | 0.250 |
Why?
|
| Middle Aged | 58 | 2024 | 214419 | 0.250 |
Why?
|
| Regional Blood Flow | 6 | 2010 | 1501 | 0.230 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 1419 | 0.220 |
Why?
|
| Pleural Neoplasms | 1 | 2008 | 621 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 2007 | 3331 | 0.220 |
Why?
|
| Nitric Oxide | 3 | 2012 | 2121 | 0.210 |
Why?
|
| Humans | 92 | 2024 | 746070 | 0.210 |
Why?
|
| Natriuresis | 5 | 2008 | 124 | 0.200 |
Why?
|
| NG-Nitroarginine Methyl Ester | 4 | 2007 | 260 | 0.200 |
Why?
|
| Mesothelioma | 1 | 2008 | 826 | 0.200 |
Why?
|
| Albuminuria | 3 | 2010 | 650 | 0.190 |
Why?
|
| Female | 60 | 2024 | 382129 | 0.190 |
Why?
|
| Uricosuric Agents | 2 | 2017 | 26 | 0.180 |
Why?
|
| Arm | 1 | 2003 | 580 | 0.180 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 6931 | 0.180 |
Why?
|
| p-Aminohippuric Acid | 5 | 2010 | 36 | 0.180 |
Why?
|
| Male | 56 | 2023 | 351098 | 0.180 |
Why?
|
| Feeding Behavior | 1 | 2012 | 3156 | 0.180 |
Why?
|
| Nitric Oxide Synthase | 3 | 2007 | 910 | 0.170 |
Why?
|
| Information Services | 1 | 2000 | 235 | 0.160 |
Why?
|
| Enzyme Inhibitors | 4 | 2007 | 3695 | 0.160 |
Why?
|
| Blood Flow Velocity | 2 | 2013 | 1367 | 0.150 |
Why?
|
| Blood Pressure Determination | 2 | 2018 | 626 | 0.150 |
Why?
|
| Adult | 53 | 2024 | 214969 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2008 | 2068 | 0.150 |
Why?
|
| Hyperemia | 2 | 2012 | 220 | 0.150 |
Why?
|
| Vasoconstriction | 3 | 2006 | 595 | 0.140 |
Why?
|
| Manometry | 2 | 2012 | 445 | 0.140 |
Why?
|
| Vitamin D Deficiency | 2 | 2017 | 1356 | 0.140 |
Why?
|
| Complementary Therapies | 1 | 2000 | 479 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 9 | 2016 | 2142 | 0.140 |
Why?
|
| Overweight | 3 | 2023 | 2385 | 0.140 |
Why?
|
| Ergocalciferols | 1 | 2017 | 110 | 0.130 |
Why?
|
| Treatment Outcome | 12 | 2023 | 63664 | 0.130 |
Why?
|
| Infusions, Intravenous | 4 | 2010 | 2206 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2016 | 10719 | 0.130 |
Why?
|
| Hypercholesterolemia | 1 | 2023 | 1146 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2008 | 4276 | 0.130 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2009 | 132 | 0.130 |
Why?
|
| Sodium | 3 | 2010 | 1604 | 0.120 |
Why?
|
| Nurses | 1 | 2024 | 2441 | 0.120 |
Why?
|
| Carbamates | 1 | 2016 | 200 | 0.120 |
Why?
|
| Pulsatile Flow | 2 | 2006 | 316 | 0.120 |
Why?
|
| Thiazoles | 2 | 2005 | 1487 | 0.110 |
Why?
|
| Aging | 5 | 2006 | 8485 | 0.110 |
Why?
|
| Pandemics | 2 | 2023 | 8434 | 0.110 |
Why?
|
| Double-Blind Method | 6 | 2017 | 12208 | 0.110 |
Why?
|
| Diabetic Nephropathies | 4 | 2005 | 1017 | 0.100 |
Why?
|
| Plethysmography | 1 | 2012 | 173 | 0.100 |
Why?
|
| Medical Informatics | 1 | 1999 | 728 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1876 | 0.100 |
Why?
|
| Vitamins | 2 | 2017 | 1611 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2023 | 2113 | 0.090 |
Why?
|
| Sodium Chloride, Dietary | 4 | 2011 | 286 | 0.090 |
Why?
|
| Sex Factors | 5 | 2007 | 10278 | 0.090 |
Why?
|
| Piperazines | 2 | 2005 | 2469 | 0.090 |
Why?
|
| Psychotherapy, Brief | 1 | 2011 | 115 | 0.090 |
Why?
|
| Aged | 18 | 2023 | 164222 | 0.090 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 15306 | 0.090 |
Why?
|
| Environmental Exposure | 1 | 2024 | 4315 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 2278 | 0.080 |
Why?
|
| Candy | 1 | 2007 | 36 | 0.080 |
Why?
|
| Secretory Vesicles | 1 | 2008 | 121 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2024 | 53219 | 0.080 |
Why?
|
| Genotype | 6 | 2008 | 12775 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2000 | 3790 | 0.080 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2009 | 231 | 0.070 |
Why?
|
| Flavanones | 1 | 2007 | 72 | 0.070 |
Why?
|
| Postmenopause | 3 | 2009 | 2461 | 0.070 |
Why?
|
| Hemodynamics | 7 | 2005 | 4187 | 0.070 |
Why?
|
| Piperidines | 1 | 2016 | 1634 | 0.070 |
Why?
|
| Cough | 1 | 2011 | 584 | 0.070 |
Why?
|
| Edema | 1 | 2011 | 755 | 0.070 |
Why?
|
| Dietary Supplements | 2 | 2017 | 3324 | 0.070 |
Why?
|
| Enalapril | 2 | 2000 | 327 | 0.070 |
Why?
|
| Fruit | 1 | 2012 | 1150 | 0.070 |
Why?
|
| Vegetables | 1 | 2012 | 1188 | 0.070 |
Why?
|
| Color | 1 | 2007 | 296 | 0.070 |
Why?
|
| Brain | 1 | 2013 | 26597 | 0.070 |
Why?
|
| Hydrocortisone | 3 | 2001 | 1776 | 0.070 |
Why?
|
| Genetic Linkage | 2 | 2005 | 2365 | 0.070 |
Why?
|
| Family Health | 2 | 2002 | 1255 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2019 | 8370 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2016 | 3966 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2011 | 983 | 0.060 |
Why?
|
| Public Health | 1 | 2018 | 2624 | 0.060 |
Why?
|
| Angiotensins | 1 | 2005 | 142 | 0.060 |
Why?
|
| Psychomotor Performance | 1 | 2013 | 1859 | 0.060 |
Why?
|
| Brachial Artery | 2 | 2016 | 360 | 0.060 |
Why?
|
| Medical Records | 1 | 2010 | 1389 | 0.060 |
Why?
|
| Food Labeling | 1 | 2007 | 179 | 0.060 |
Why?
|
| Blood Volume | 1 | 2006 | 551 | 0.060 |
Why?
|
| Dementia, Vascular | 1 | 2006 | 123 | 0.060 |
Why?
|
| Age Factors | 5 | 2008 | 18145 | 0.060 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 2030 | 0.060 |
Why?
|
| Systole | 2 | 2003 | 928 | 0.060 |
Why?
|
| Diastole | 2 | 2003 | 775 | 0.060 |
Why?
|
| Pulse | 1 | 2003 | 218 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 742 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2011 | 11941 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2018 | 4265 | 0.060 |
Why?
|
| Fingers | 1 | 2006 | 503 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 786 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 664 | 0.050 |
Why?
|
| Contraceptives, Oral | 1 | 2005 | 550 | 0.050 |
Why?
|
| Phenotype | 6 | 2008 | 16250 | 0.050 |
Why?
|
| Body Mass Index | 6 | 2023 | 12633 | 0.050 |
Why?
|
| Linear Models | 3 | 2007 | 5822 | 0.050 |
Why?
|
| Homeostasis | 2 | 2010 | 3261 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 15010 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2007 | 1559 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2001 | 96 | 0.050 |
Why?
|
| Adolescent | 10 | 2018 | 86212 | 0.050 |
Why?
|
| Mast Cells | 1 | 2008 | 1425 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2001 | 64 | 0.050 |
Why?
|
| Lisinopril | 1 | 2001 | 54 | 0.050 |
Why?
|
| Blood Glucose | 3 | 2007 | 6213 | 0.050 |
Why?
|
| Potassium | 2 | 2002 | 1313 | 0.050 |
Why?
|
| Kidney Function Tests | 3 | 2009 | 664 | 0.040 |
Why?
|
| Kidney Glomerulus | 1 | 2003 | 680 | 0.040 |
Why?
|
| Renal Veins | 1 | 2000 | 102 | 0.040 |
Why?
|
| Alcoholism | 1 | 2010 | 1921 | 0.040 |
Why?
|
| Drug Design | 1 | 2005 | 1055 | 0.040 |
Why?
|
| MEDLINE | 1 | 1999 | 120 | 0.040 |
Why?
|
| United States | 4 | 2024 | 70368 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2000 | 289 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2002 | 962 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 961 | 0.040 |
Why?
|
| Patient Selection | 1 | 2010 | 4192 | 0.040 |
Why?
|
| Acrylates | 1 | 1997 | 77 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 1997 | 403 | 0.040 |
Why?
|
| Radioimmunoassay | 1 | 2016 | 871 | 0.030 |
Why?
|
| Risk Factors | 8 | 2020 | 72413 | 0.030 |
Why?
|
| Cognition | 1 | 2013 | 6772 | 0.030 |
Why?
|
| Young Adult | 5 | 2023 | 57114 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2016 | 167 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 7935 | 0.030 |
Why?
|
| American Heart Association | 1 | 2000 | 1014 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1997 | 356 | 0.030 |
Why?
|
| Time Factors | 5 | 2017 | 39589 | 0.030 |
Why?
|
| Diabetes Mellitus | 3 | 2011 | 5765 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 5329 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 453 | 0.030 |
Why?
|
| Demography | 1 | 1999 | 1629 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 1563 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2018 | 5895 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 78293 | 0.030 |
Why?
|
| Health Education | 1 | 2001 | 1045 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 12272 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 1394 | 0.030 |
Why?
|
| Exercise | 1 | 2010 | 5687 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 2370 | 0.030 |
Why?
|
| Menopause | 2 | 2000 | 1615 | 0.030 |
Why?
|
| Thiophenes | 1 | 1997 | 586 | 0.030 |
Why?
|
| Peptides | 1 | 2005 | 4312 | 0.030 |
Why?
|
| Premenopause | 1 | 1997 | 1033 | 0.030 |
Why?
|
| Publishing | 1 | 2000 | 828 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 3011 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1994 | 619 | 0.030 |
Why?
|
| Glucose | 1 | 2003 | 4303 | 0.020 |
Why?
|
| Boston | 2 | 2017 | 9209 | 0.020 |
Why?
|
| Imidazoles | 1 | 1997 | 1165 | 0.020 |
Why?
|
| Endocrine Glands | 1 | 1991 | 101 | 0.020 |
Why?
|
| Obesity | 2 | 2023 | 12670 | 0.020 |
Why?
|
| Air Pollution | 1 | 2024 | 2288 | 0.020 |
Why?
|
| Syndrome | 1 | 1997 | 3245 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2008 | 21676 | 0.020 |
Why?
|
| Central Nervous System Depressants | 1 | 2011 | 160 | 0.020 |
Why?
|
| Diet | 1 | 2008 | 7881 | 0.020 |
Why?
|
| Creatinine | 2 | 2008 | 1848 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2000 | 2558 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2017 | 2906 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 15367 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2024 | 40505 | 0.020 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2008 | 13 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 4858 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2011 | 800 | 0.020 |
Why?
|
| Creatine | 1 | 2010 | 414 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 6459 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 1997 | 2685 | 0.020 |
Why?
|
| Culture Media | 1 | 2008 | 895 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1999 | 3189 | 0.020 |
Why?
|
| Inulin | 2 | 1999 | 81 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 2008 | 515 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2000 | 7812 | 0.020 |
Why?
|
| Gastroparesis | 1 | 2007 | 132 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 57552 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 38752 | 0.020 |
Why?
|
| Ethanol | 1 | 2011 | 1316 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2006 | 608 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 2005 | 341 | 0.010 |
Why?
|
| Infertility | 1 | 2011 | 647 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 2007 | 383 | 0.010 |
Why?
|
| Diabetic Neuropathies | 1 | 2007 | 401 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2000 | 7272 | 0.010 |
Why?
|
| Animals | 4 | 2001 | 166308 | 0.010 |
Why?
|
| Cross-Sectional Studies | 3 | 2010 | 25174 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2007 | 776 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 14537 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 2007 | 811 | 0.010 |
Why?
|
| France | 1 | 2003 | 497 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3426 | 0.010 |
Why?
|
| Data Collection | 1 | 2011 | 3287 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2011 | 1581 | 0.010 |
Why?
|
| Italy | 1 | 2003 | 824 | 0.010 |
Why?
|
| Algorithms | 1 | 2020 | 13798 | 0.010 |
Why?
|
| Motor Activity | 1 | 2010 | 2666 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2000 | 311 | 0.010 |
Why?
|
| Zona Glomerulosa | 1 | 1999 | 87 | 0.010 |
Why?
|
| Age of Onset | 1 | 2005 | 3241 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2008 | 6332 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 35781 | 0.010 |
Why?
|
| Glucose Clamp Technique | 1 | 1999 | 246 | 0.010 |
Why?
|
| Complement Pathway, Alternative | 1 | 1998 | 117 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 2007 | 1246 | 0.010 |
Why?
|
| Massachusetts | 1 | 2010 | 8593 | 0.010 |
Why?
|
| Hematocrit | 1 | 1999 | 618 | 0.010 |
Why?
|
| Observer Variation | 1 | 2003 | 2574 | 0.010 |
Why?
|
| Risk | 1 | 2009 | 9521 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2339 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 10348 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 2891 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2001 | 1109 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 1599 | 0.010 |
Why?
|
| Posture | 1 | 1999 | 949 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12018 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 16652 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 20812 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 29296 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17435 | 0.000 |
Why?
|
| Models, Biological | 1 | 2002 | 9443 | 0.000 |
Why?
|
| Heart | 1 | 1998 | 4361 | 0.000 |
Why?
|
| Insulin | 1 | 1999 | 6470 | 0.000 |
Why?
|